# A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults

> **NCT07749651** · PHASE1 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Cutaneous Lupus Erythematosus(CLE)

## Interventions

- **DRUG:** SHR-7012 injection ; placebo
- **DRUG:** SHR-7012 injection ; placebo
- **DRUG:** SHR-7012 injection ; placebo
- **DRUG:** SHR-7012 injection ; placebo
- **DRUG:** SHR-7012 injection ; placebo ;

## Key facts

- **NCT ID:** NCT07749651
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-19
- **Primary completion:** 2027-04
- **Final completion:** 2027-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07749651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07749651, "A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07749651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*